Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

NCT02093962 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
265
Enrollment
INDUSTRY
Sponsor class

Stopped At the interim analysis, the futility boundary was not met and the study was stopped due to insufficient efficacy.

Conditions

Interventions

Sponsor

ImmunoGenesis

Collaborators